Roche announces phase III study of Tecentriq plus Abraxane meets co─primary endpoint for metastatic triple negative breast cancer

Roche announced that the phase III IMpassion130 study met its co─primary endpoint of progression─free survival (PFS). Results demonstrated that the combination of Tecentriq (atezolizumab) plus chemotherapy

More From BioPortfolio on "Roche announces phase III study of Tecentriq plus Abraxane meets co─primary endpoint for metastatic triple negative breast cancer"